Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivir Narrows Research Strategy To Cancer And Infectious Diseases

This article was originally published in The Pink Sheet Daily

Executive Summary

Sweden's Medivir drops neuropathic pain research to focus on oncology and infectious diseases while streamlining its R&D process by partnering with India’s GVK BIO, in a bid to cut costs and raise flexibility.

You may also be interested in...



Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus

Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.

Global AMR R&D Hub Launches Dynamic Data Dashboard

The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.

Manipulating Metabolism: Lilly Links With UK Biotech Sitryx

Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel